Please login to the form below
Deal Watch table for February 2014
Table listing all the major pharma mergers, acquisitions and collaborations in the past month
This table lists all the major pharma collaborations, acquisitions and mergers agreed during February 2014.
For an indepth analysis of these deals, read 'Pharma deals during February 2014'
| Licensor acquired / licensee acquirer | Deal type | Product / technology | Headline ($m) |
| Forest Laboratories / Actavis | Company acquisition | Speciality pharma with strong CNS portfolio | 25,000 |
| Ablynx / Merck & Co | Collaboration | Nanobody candidates to target “immune checkpoint modulators” | 2,331 |
| Cadence Pharmaceuticals / Mallinckrondt | Company acquisition | Ofirmev (acetaminophen) for pain | 1,300 |
| Adcock Ingram / CFR Pharmaceuticals | Acquisition termination | South African generics company | 1,225 |
| Medpace / Cinven | Acquisition – majority shareholding | US mid-sized CRO with global presence | 915 |
| Cellectis / Servier | Licence | Product candidates for solid tumours, UCART19 (allogenic CAR-T) for leukaemia and lymphomas (6 candidates in total) | 850 |
| PreCision Dermatology / Valeant Pharmaceuticals | Company acquisition | Medical dermatological products | 500 |
| Crescendo Bioscience / Myriad Genetics | Company acquisition | Medical diagnostic tool for autoimmune diseases | 270 |
| Discuva / Roche | Collaboration | Antibiotics to target multi-drug resistant Gram negative bacteria | 201 |
| Ardelyx (formerly Nteryx) / Sanofi | Licence1 | NaP2b inhibitor programme for ESRD2 and CKD3 | 198 |
| Zosano (formerly Macroflux) / Novo Nordisk | Development | Semaglutide once weekly, ZP Patch Technology | 115 |
| Andromeda / Teva Pharmaceutical Industries | Licence termination | DiaPep277 for type 1 diabetes patients | 72 |
| Manchester Pharmaceuticals / Retrophin | Company acquisition | Rare disease company with marketed products in US (Chenodal to treat CTX4) | 63 |
| Apricus Biosciences (formerly NexMed) / Recordati | Licence | Vitaros topical treatment for erectile dysfunction | 51 |
| Abide Therapeutics / Celgene | Option and equity investment | Inflammatory and immunology target for catalytic of serine hydrolases for CNS signalling | 50 |
| 4-Antibody AG / Aegenus | Company acquisition | Retrocyte Display technology platform | 40 |
| UDG Healthcare / Professional Compounding Centers of America | Company acquisitions | UDG subsidiaries : The Specials Laboratory Holdings, Craig & Hayward, Arjun Products | 39 |
| Novo Nordisk / Innate Pharma | Licence with equity partial payment | Phase II ready Anti-NKG2A antibody “immune checkpoint inhibitor” | 30 |
| Servier / MacroGenics | Option exercise | MGD006, a DART-based product candidate for haematological malignancies | 15 |
| Forest Labs / Hospira (via Mayne Pharma) | Acquisition products | Esgic, ESGIC PLUS, Lorcet, LORCET PLUS – portfolio of pain products | 12 |
1. Co-promotion rights in US
2. Endstage renal disease
3. Chronic kidney disease
4. Cerebrotendinous xanthomatosis
Subscribe to our email news alerts
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- AbbVie’s Rinvoq receives FDA approval for Crohn’s disease
- Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cancer
- AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer
- Novo Nordisk announces positive phase 3 results for oral weight-loss drug
- COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP
- FDA approves Blueprint Medicines’ Ayvakit for indolent systemic mastocytosis
- Medscape Medical Affairs Selected as Finalist for 2023 Communiqué Awards
- COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Gene therapy, gene editing and perspectives on future use in Parkinson’s disease
- Patient Clinical Trial & Communications Plan Review: A Customer Story
- Shining a Spotlight on Women’s Health Education Outcomes at ACOG 2023
PMHub
Syneos Health®
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...
